CG Oncology (CG Oncology) Debt-to-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Debt-to-Asset?

CG Oncology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.22 Mil. CG Oncology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.18 Mil. CG Oncology's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $579.11 Mil. CG Oncology's debt to asset for the quarter that ended in Mar. 2024 was 0.00.

CG Oncology Debt-to-Asset Historical Data

The historical data trend for CG Oncology's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Debt-to-Asset Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Asset

0.26

0.11

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial			0.11	-	-	-	-

Competitive Comparison of CG Oncology's Debt-to-Asset

For the Biotechnology subindustry, CG Oncology's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where CG Oncology's Debt-to-Asset falls into.

CG Oncology Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

CG Oncology's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.217	+	0.244)	/	199.301
	=	0.00

CG Oncology's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.22	+	0.184)	/	579.108
	=	0.00

CG Oncology (NAS:CGON) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

CG Oncology Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of CG Oncology's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024